Cancer stem cells in bladder cancer: A revisited and evolving concept

Urology, Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Current opinion in urology (Impact Factor: 2.33). 09/2010; 20(5):393-7. DOI: 10.1097/MOU.0b013e32833cc9df
Source: PubMed


Recently, the prospective isolation and characterization of cancer stem cells (CSCs) from various human malignancies revealed that they are resistant to radiation and chemotherapies. Therefore, CSCs may be the 'roots' and ideal target for therapeutic intervention. Here, we will focus on reviewing the historical perspective, recent literatures on bladder cancer stem cells and their clinical implications.
CSCs have been prospectively isolated from bladder cancer tissues from patient specimens, established cancer cell lines and xenografts, based on the expression of a combination of cell surface receptors, cytokeratin markers, drug transporters and the efficient efflux of the Hoechst 33,342 dye (side population). Further, global gene expression profiling of CSCs revealed an activated gene signature of CSCs similar to that of aggressive bladder cancer, supporting the concept that a tumor cell subpopulation is contributing to bladder cancer progression. Finally, our studies on the preclinical targeting of bladder CSCs in vitro and in xenografts using a blocking antibody for CD47 reveal promising efficacy.
Functionally distinct CSCs exist in human bladder cancer and can be prospectively isolated. Continuing research will be important to identify their cell of origin, programs balancing self-renewal and differentiation and to identify additional therapeutic options to target bladder CSCs.

Full-text preview

Available from:
  • Source
    • "This receptor is strongly overexpressed in several cancer types including both hematological and solid tumors[80,91,109,110]. A high CD47 expression has been a poor prognostic factor for patients with these diseases[80,111,112]. CD47 is also highly expressed in tumor initiating cells (TICs) or cancer stem cells (CSC) where it is a marker of more aggressive tumor cells, with higher metastatic potential, and less sensitive to engulfment by macrophages, thereby escaping from immune surveillance while increasing cell proliferation through activation of the PI3K/Akt pathway[92,113114115116. Therefore, CD47 becomes an attractive target for therapeutic approaches with both antitumor and antiinflammatory properties and anti-CD47 antibodies are being tested with positive results in preclinical and clinical settings[80,111,112,117]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation is a component of the tumor microenvironment and represents the 7th hallmark of cancer. Chronic inflammation plays a critical role in tumorigenesis. Tumor infiltrating inflammatory cells mediate processes associated with progression, immune suppression, promotion of neoangiogenesis and lymphangiogenesis, remodeling of extracellular matrix, invasion and metastasis, and, lastly, the inhibition of vaccine-induced antitumor T cell response. Accumulating evidence indicates a critical role of myeloid cells in the pathophysiology of human cancers. In contrast to the well-characterized tumor-associated macrophages (TAMs), the significance of granulocytes in cancer has only recently begun to emerge with the characterization of tumor-associated neutrophils (TANs). Recent studies show the importance of CD47 in the interaction with macrophages inhibiting phagocytosis and promoting the migration of neutrophils, increasing inflammation which can lead to recurrence and progression in lung cancer. Currently, therapies are targeted towards blocking CD47 and enhancing macrophage-mediated phagocytosis. However, antibody-based therapies may have adverse effects that limit its use.
    Full-text · Article · Jan 2016 · Mediators of Inflammation
  • Source
    • "CSCs are a distinct subset of cancer cells, characterized by unlimited self-renewal, high metastatic potential, long lifespan, and great resistance to therapy [105] [106]. This distinct population is recently evaluated in many solid organ cancers, including bladder cancer [107]. Aberrant activation of the Wnt, Notch and Hedgehog pathways has been implicated in functions ranging from tumor initiation to CSC maintenance and have recently been discovered in urothelial carcinomas [108] [109]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.
    Full-text · Article · Feb 2015 · Current Drug Targets
  • Source
    • "Inhibition is mediated by fyn, p38 MAPK and caspase signaling pathways, resulting in endothelial cell apoptosis. VEGFR2 수용체의 인산화를 억제하는 것으로 알려져 있 는데[[50,53]. 이미 CD47의 작용을 차단하는 여러 가지 단클론항체들이 림프종, 방광암, 직장암, 교아세포종, "
    [Show abstract] [Hide abstract]
    ABSTRACT: Thrmobospondin-1 is the multifunctional protein that modulates endothelial cell and tumor cell behavior via several cell surface receptors and inhibits angiogenesis. In vitro, thrombospondin-1 alters adhesion, proliferation, motility, and survival of endothelial and cancer cells. Studies have confirmed that increased TSP-1 expression suppresses growth or metastasis of some tumors and inhibits angiogenesis. In the past three decades, inhibitors of angiogenesis have been developed as regulators target the vascular endothelial growth factor (VEGF) signaling pathway and small molecule tyrosine kinase inhibitors have been clinically approved. TSP-1 has several functional domain structures and inhibits tumor angiogenesis by engaging receptors CD36 and CD47. TSP-1 binding to CD47 dissociates it from VEGFR2, inhibiting downstream AKT activation and functional responses of endothelial cells to VEGF. Recently, macrophage phagocytosis and cytotoxic T-cell induction of tumor cells mediated by CD47-specific blocking antibodies have been proposed. These findings provide a new therapeutic paradigm for elinination of cancer cells and inhibition of angiogenesis of tumor by TSP-1.
    Preview · Article · Jan 2015
Show more